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Intravenous human immunoglobulin G (IgG) has been a standard therapy for some inflammatory 
and autoimmune diseases. Recent evidence demonstrates that intravenous IgG can impair cancer 
cells. However, some evidence prove that cancer cells can produce and secret IgG, and the tumor 
cell-derived IgG promotes tumor initiation. This suggests that there might be an unrecognized 
effect of IgG on cancer cells. In addition, there is no study investigating whether or not IgG 
application benefits cancer patients receiving chemotherapeutics. Thus, the aim of this study was 
to investigate the effect of therapeutically used IgG on colon cancer in the presence of 
oxaliplatin, a tranditional therapy of colon cancer. 
Methods  
A series of low-passage patient-derived colon cancer cell lines and patient-derived xenograft 
carrying mice were treated with IgG (PRIVIGEN®) and oxaliplatin. The cell viability and tumor 
volume were evaluated, respectively. In order to evaluate cell death, cells were stained by 
Annexin V and propidium iodide and flow cytometry cell sorting analyses were performed. In 
addition, to evaluate tumor cell-derived IgG, colon cancer cells were stained by goat anti-human 
IgG antibody, the levels of cell-derived IgG were determined by flow cytometry, and the activity 
of ERK-signaling was evaluated by western blot.  
Results  
The present study demonstrated that human normal IgG (PRIVIGEN®) failed to significantly 
influence tumor cell viability and tumor growth; however, it significantly inhibited the cytotoxic 
activity of oxaliplatin in vitro but fail to significantly impair the anti-tumor effect of oxaliplatin in 
vivo. In addition, this study proved that colon cancer cells produced IgG and the levels of tumor 
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cell-derived IgG were positively correlated with oxaliplatin resistance. When evaluating the ERK 
activity, this study proved that oxaliplatin induced the activation of ERK; however, PRIVIGEN® 
IgG inhibits ERK activity. Interestingly, inhibition of ERK signaling by PD98059 and U0126, 
two traditional inhibitors of the ERK pathway, also reduced oxaliplatin-induced cell death. 
Conclusions  
The present study demonstrates that IgG impairs the anti-cancerous effect of oxaliplatin and this 
might dependent on the interaction between IgG and ERK: IgG inhibits ERK activity. Thus, the 
present study implies that application of therapeutical IgG to treating patients, which are 




1.1 Colon cancer 
1.1.1 Epidemiology  
Following lung cancer (11.6% of the total cases), female breast cancer (11.6%), and prostate 
cancer (7.1%), colorectal cancer (6.1%) is the fourth common cancer in the world [1]. 
Interestingly, it has been demonstrated that the incidence of colorectal cancer varies widely 
worldwide (Fig. 1). For example, Arnold et al. reported that in 2012, the estimated incidence of 
colorectal cancer in males varied from 1.5 per 100,000 in some African countries, such as 
Gambia and Mozambique, to over 40 per 100,000 in several countries in Europe and Asia, such 
as Slovakia (61.6 per 100,000), Hungary (58.9 per 100,000) and the Republic of Korea (58.7 per 
100,000) [2]. In addition, the incidence and mortality of colorectal cancer is rising rapidly in 
many low-income and middle-income countries; however, it is stabilizing or decreasing in highly 
developed countries [2]. This might be due to the changes in lifestyle and dietary patterns in these 
areas [3, 4]. 
According to the UK national statistics, two-third of colorectal cancers are colon cancer [5, 6]. In 
contrast to the decreasing incidence of rectal cancer, the incidence of colon cancer increased 
during the last decades in a number of western countries, such as USA, Canada, Australia, New 
Zeeland, and European countries [5]. In addition, until 2035, the mortality of colon cancer in 
USA is predicted to increase from 1.8 per 100,000 to 2.3 per 100,000 and in UK, the mortality 




Fig. 1. Estimated age-standardized incidence rates of colon cancer in 2018, both sexes and all ages 
(https://gco.iarc.fr/). The incidence of colon cancer in Canada, Australia, and several countries in Europe is higher 
than that in African countries.  
 
1.1.2 Mechanisms of colon cancer development 
Several studies prove that some life style factors, such as smoking [8], dietary patterns [9], and 
lack of physical activity [10], are risk factors of colon cancer. For example, Cheng et al. 
investigated the relationship between cigarette smoking and the incidence of colon cancer; they 
observed that cigarette smoking was associated with an increased risk of colon cancer, and 
current smokers had a significantly higher risk of proximal colon cancer than distal colon cancer 
[8]. In addition, Kyu et al. systematic reviewed 19 studies, including 53,929,648 patients, and 
they observed that the risk of colon cancer among individuals in the low active, moderately 
active, and highly active categories was decreased by 10%, 17%, and 21%, respectively, when 
they were compared to insufficiently active individuals [10]. Unfortunately, the mechanisms, how 
these life style factors contribute to the development of colon cancer, is still unclear and genetic 
alteration might be involved [11, 12]. For example, Limsui et al demonstrated that smoking was 
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positively correlated with the mutation of BRAF, a master regulator of the initiation of colon 
cancer [13].  
A large body of evidence proves that colon cancer is not a single disease but rather a collection of 
several distinct diseases with diverse molecular background and clinicopathological 
manifestations [14]. According to this theory, two pathways are invovled in the development of 
colon cancer: the adenoma-carcinoma pathway and the serrated neoplasia pathway [15].  
Based on the concept of traditional adenoma-carcinoma pathway, colon cancer cells begin as a 
noncancerous growth and develop into a tubular adenomatous polyp. Subsequently, the tubular 
adenomatous polyp can evolve into an early adenoma, an advanced adenoma, and finally 
develops into colon cancer [16]. Usually, in this pathway, the colon cancer develops slowly. In 
addition, the adenoma-carcinoma pathway is characterized by chromosomal instability [17]. This 
is supported by the fact that the mutation of tumor suppressor genes, such as p53 [18], and tumor-
promoting genes, such as KRAS and BRAF [19], have been observed in the majority of early 
neoplastic lesions [20], and several studies have demonstrated that this is a master molecular and 
pathophysiological event in the initiation and formation of colon cancer [18-21].  
Compared to the adenoma-carcinoma pathway, the serrated neoplasia pathway is a novel concept 
[22, 23]. According to this concept, colon cancer evolves from a subset of polyps, termed sessile 
serrated polyps, which account for about 5%-10% of all polyps [24]. Distinct from the adenoma-
carcinoma pathway, tumors from the serrated neoplasia pathway are characterized by 
microsatellite and epigenetic instability [24]. Microsatellite instability is caused by the inability 
of DNA mismatch repair and it manifests as increase or decrease of the length of microsatellite 
repeats [25]. In addition, epigenetic instability of colon cancer is characterized by aberrant DNA 
methylation [15].  
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1.1.3 Diagnosis and chemotherapy 
Colonoscopy and tissue biopsy is still the “gold standard” method for diagnosis of colon cancer, 
and the sensitivity of this method is about 94.7% (95% confidence interval, 90% and 97%) [26]. 
In addition, colonoscopy in combination with barium enema, computed tomography 
colonography and the level of carcinoembryonic antigen (CEA) might improve the accuracy of 
colonoscopy [26].  
CEA is derived from endoderm, and it is the most commonly used tumor marker in the diagnosis 
of colon cancer [27, 28]. It has been reported that overexpression of CEA is occurring in more 
than 90% of colorectal cancer patients [29]. However, CEA also expresses in other tumors, such 
as gastric cancer [30, 31], lung cancer [32], and ovarian cancer [30, 33]. This limits the diagnostic 
accuracy of CEA.  
Since early colon cancer usually has no symptoms, it is important to perform screening to detect 
the tumor. Usually, the individual risk statuses decide when and how start to screen [34]. For 
example, for people at an average risk for colon cancer, the screening should be offered at age 50 
years by one of the following options: Fecal occult blood testing, sigmoidoscopy, fecal occult 
blood testing in combination with flexible sigmoidoscopy, colonoscopy or double-contrast 
barium enema [34]. In addition, people with a family history of colorectal cancer or hereditary 
nonpolyposis have a high risk of developing colon cancer [35]. These people should be suggested 
to be screened by colonoscopy at 10 years younger than the earliest diagnosis in their family [34].  
In order to determine appropriate strategies for distinct patients, the tumor (T), node (N), 
metastasis (M) classification (Table 1) has been developed by Union for International Cancer 
Control [36, 37]. For patients without distant metastasis, such as Stage 0 and Stage I, surgical 
resection is the main or first-line treatment. However, for patients with metastasis, such as Stage 
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III and Stage IV, surgery is unlikely to cure these cancers and chemotherapy is the main 
treatment.  
 
Table 1. UICC staging system of colon carcinoma (AJCC 8th edition)  
 
UICC T N M 
Stage 0 Tis N0 M0 
Stage I T1-T2 N0 M0 




























Stage IV any T any N M1a or M1b or M1c 
 
Tis: carcinoma in situ, intramucosal carcinoma; T1: tumor grows through the muscularis mucosa but not invades 
through the muscularis propria; T2: tumor invades muscularis propria; T3: tumor grows through the muscularis 
propria and invades the pericolorectal tissues; T4a: tumor grows through the visceral peritoneum; T4b: tumor 
directly invades or adheres to other adjacent organs or structures; N0: no regional lymph node metastasis; N1: 1-3 
regional lymph node metastases; N1a: 1 regional lymph node metastasis; N1b: 2-3 regional lymph node metastases; 
N1c: no regional lymph node metastasis but there are tumor deposits in the subserosa, mesentery or 
nonperitonealized pericolic or perirectal/mesorectal tissues; N2: 4 or more regional lymph nodes metastases; N2a: 4-
6 regional lymph node metastases; N2b: 7 or more regional lymph node metastases; M1: no other site or organ 
metastases; M1a:metastasis in one organ or site without peritoneal metastasis; M1b: metastases in two or more sites 
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or organs without peritoneal metastasis; M1c: metastasis to the peritoneal surface alone or with other site or organ 
metastases [38]. 
 
1.2 Oxaliplatin  
1.2.1 Platinum compounds 
Platinum compounds and DNA can form platinum-DNA adducts and inhibit DNA synthesis and 
repair. In 1970s, it has been proven that cisplatin, the first-generation of platinum compound, 
could impair cancer cells [39]. Subsequently, around 3,000 platinum derivatives were synthesized 
[39]. Unfortunately, only 30 compounds were tested in clinical trials and most of them failed to 
impair tumors in patients [39]. Today, only four compounds are approved and used clinically 
(Fig. 2): Cisplatin, the first generation compound; carboplatin and nedaplatin, the second-
generation compounds; oxaliplatin, the third-generation platinum compound. In addition, some 
platinum complexes, such as triplatin tetranitrate, phenanthriplatin, picoplatin, and satraplatin are 
still under clinical investigation [39].  
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1.2.2 Mechanisms of the cytotoxic activity of oxaliplatin 
Like other platinum derivatives, the cytotoxic effect of oxaliplatin (transl-L-1,2-
diaminocyclohexane, C8H14N2O4Pt) is dependent on the platinum-DNA adduct (Fig. 2). 
However, compared to cisplatin, the amine groups are replaced by diaminocyclohexane (Fig. 2). 
This leads to a more stable binding between platinum and DNA [40]. Indeed, several preclinical 
studies proved that, compared to cisplatin, oxaliplatin is more effective in inhibiting DNA 
synthesis [41]. In addition, previous studies demonstrated that diaminocyclohexane enhances the 
cytotoxicity of oxaliplatin, and reduces cross-resistance between oxaliplatin and other platinum 
derivatives in vitro. Notably, the oxaliplatin-induced DNA damage can lead to the expression of 
excision repair cross complementation group 1 (ERCC1), which triggers cancer cell resistance to 
oxaliplatin [42, 43].  
 
Fig. 2. Platinum leads to DNA damage. Platinum compounds, such as cisplatin, carboplatin, nedaplatin and 
oxaliplatin, can bind to strands of DNA and form a platinum-DNA adducts. This can impair the replication of DNA.  
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Several studies proved that DNA damage is not the sole mechanism of oxaliplatin cytotoxicity 
[44, 45]. For example, Santoro et al. reported that oxaliplatin could activate p38 mitogen-
activated protein kinase (p38); a master protein of the mitogen-activated protein kinases 
(MAPKs) pathway and inhibition of p38 activity significantly impairs the toxic effects of 
oxaliplatin. Interesting, the same research group observed that oxaliplatin can induce the activity 
of extracellular signal-regulated kinases 1 and 2 (ERK), another master protein of MAPKs 
pathway. Surprisingly, inhibition of ERK significantly enhances the cytotoxicity of oxaliplatin. 




Fluorouracil (5-FU), an analogue of uracil, was synthesized by Duschinsky et al. in 1957 [46]. 
Various mechanisms, which contribute to the cytotoxic effect of 5-FU, have been reported [47]. 
For example, 5-fluoro-deoxyuridine-monophosphate (5-FdUMP), a metabolite of 5-FU, can form 
a complex with thymidylate synthase and inhibit the synthesis of DNA [48]. 5-fluoro-
deoxyuridinetriphosphate (5-FdUTP), another metabolite of 5-FU, incorporates into DNA and 
impairs DNA stability [49]. In addition, 5-FU can also be transformed into 5-fluorouridine-
triphosphate (5-FUTP), which incorporates into RNA instead of uridine triphosphate (UTP) and 
inhibits the synthesis of RNA [50].  
Although numerous preclinical studies proved that 5-FU is a promising chemotherapy for several 
types of cancers, such as colon cancer [51], breast cancer [52]and pancreatic cancer [53], there 
are some serious adverse events of high dose 5-FU, such as central nervous system neutropenia 
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and febrile neutropenia [54, 55]. Thus, to reduce the dose, 5-FU is clinically given in combination 
with other chemotherapeutics, such as irinotecan and oxaliplatin [56]. 
 
1.4 Irinotecan 
Irinotecan and topotecan are camptothecin analogues, and irinotecan can be hepatically 
metabolized and converted to SN-38 which is 1,000 times more active than irinotecan itself [57]. 
Subsequently, SN-38 inhibits the activity of topoisomerase I and leads to breaks in both DNA 
strands and subsequently causes cell death. It has been reported that irinotecan can impair several 
cancers, such as colon cancer, lung cancer, and gastric cancer [58-60]. In addition, irinotecan in 
combination with leucovorin and fluorouracil (FOLFIRI) has been clinically used to treat colon 
cancer [61]. 
 
1.5 Treatment of cancer patients with immunoglobulin G 
Immunoglobulin G (IgG) is produced and released by B-lymphocytes and it is a master regulator 
of humoral immunity [62]. IgG is composed of four peptide chains, two light chains and two 
heavy chains. The heavy chains link to each other by disulfide bonds and each of them binds to a 
light chain by another disulfide bond (Fig. 3) [63]. In addition, the heavy chains and the light 
chains can be divided into variable (V) region and constant (C) region. The variable domains of 
the heavy (VH) and light (VL) chains make up the variable regions of IgG and together form the 





Fig. 3. Structure of IgG. IgG is composed of four peptide chains, two light (L) chains and two heavy (H) chains. 
Each chain can be divided into variable (V) region and constant (C) region. The light chain (CL) binds to heavy chain 
(CH1) by a disulfide bond and the two heavy chains (CH2) bind to each other via two disulfide bonds. 
 
It is a well-accepted concept that intravenous human normal IgG is helpful to treat inflammatory 
diseases [64, 65]. In addition, cytotoxic chemotherapy impairs the immune system and leads to 
severe immune deficiency in some cancer patients [66]. Thus, in order to improve the immunity 
of cancer patients receiving chemotherapeutics, intravenous human normal IgG might be a 
promising strategy. Interestingly, some preclinical studies proved that IgG can inhibit cell 
proliferation and induce cell death [67, 68]. Moreover, Shoenfeld and Fishman evaluated the anti-
cancerous effect of IgG by several experimental animal models, such as inoculation of melanoma 
or sarcoma cells to naive mice, inoculation of melanoma cells to the footpad, and inoculation of 
human tumor cells to severe combined immunodeficient mice. They observed that IgG 
significantly decreased metastatic lung foci and prolonged survival [69]. However, there is no 
study which evaluated if and how IgG regulates the cytotoxic effect of chemotherapy.   
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1.6 The aim of this dissertation 
The purpose of this study was to evaluate if intravenous human normal IgG regulates the viability 
of colon cancer cells. In addition, this study investigated the effects of IgG in combination with 
5-FU, irinotecan or oxaliplatin; three clinically used chemotherapeutic agents of colon cancer. 
 
2. Material and Methods 
2.1 Patient-derived colon carcinoma cell lines 
The fresh colon tumor tissues were obtained from colon cancer patients who underwent surgical 
resection and signed the written informed consent. This was approved by the Ethics Committee 
of the University of Rostock (reference number II HV 43/2004) in accordance with the 
declaration of Helsinki.  
The details of the processes have been described in detail in a previous study [70]. 3 × 3 × 3mm 
tumor tissue(s) was implanted into one or both sides of the flank(s) of immunodeficient mice, 
such as NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ and NMRI-Foxn1nu mice. The surveillance of the tumor 
growth was started 15 days after the implantation. Mice were euthanized when the volumes of 
tumors reached 500-1,000 mm3, and the tumor tissues were stored at -80°C. In order to develop 
colon carcinoma cell lines, the fresh human colon tumor tissues or the patient-derived colon 
carcinoma tissues were dissected into pieces and passed through a cell strainer [71]. Primary cell 
lines, which directly established from human fresh tumor tissues, are indicated with the prefix 
HROC (Hansestadt Rostock colorectal cancer) and the ID number of the patient, such as 
HROC370. Cell lines, which were derived from patient derived xenograft (PDX), are denoted 
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with additional indices. For example, Met indicates metastatic tumor, T indicating the times of 
transfer in an immunodeficient mouse, and M indicates the ID number of mice, such as 
HROC278Met T2 M2. 
HROC18, HROC46 T0 M1 (HROC46), HROC50 T1 M5 (HROC50), HROC87 T0 M2 
(HROC87), HROC131 T0 M3 (HROC131), HROC147Met (HROC147), HROC277 T0 M1 
(HROC277), HROC277Met2, HROC278Met T2 M2 (HROC278), HROC285 T0 M2 
(HROC285), HROC370, HROC374 were cultured in DMEM/F12 (1:1) (PAN-Biotech, 
Aidenbach, Germany, code P04-41500) and supplemented with 10% fetal bovine serum (FBS, 
PAN-Biotech, code P40-47500) at 37 °C in a humidified atmosphere of 5% CO2.   
In order to determinate appropriate amounts of cells for each experiment, the colon cancer cells 
were washed by phosphate buffer saline (PBS, PAN-Biotech, code P04-53500). Subsequently 
these cells were trypsinized by 1mL 0.025% trypsin/EDTA (trypsin, PAN-Biotech, code P10-
023100) at 37 °C for 5-10 minutes, and the activity of trypsin was blocked by 3-4mL medium. 
The appropriate amount of cells were determined with the help of a Neubauer chamber (Thermo 
Fisher Scientific,Waltham, USA). In addition, the materials used for cell culture were 
summarized in Table 2.  
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Table 2. Material for cell culture 
 
Devices 
Product Company Headquarters 
Centrifuge 5415 D Eppendorf Germany 
Cryo Freezing Container: Mr. FrostyTM Thermo Scientific USA 
Pasteur IPS Type A Miroplate Incubator Bio-Rad Germany 
Incubator Memmert GmbH+Co.KG Germany 
Laminar Flow MSC Advantage Thermo Scientific USA 
Light microscope: Olympus CKX 41 Olympus Deutschland GmbH  Germany 
Multistepper Eppendorf Germany 
Neubauer - Counting chamber Marienfeld Germany 
Pipetboy Integra Bioscience Germany 
Pipettes Eppendorf and Gilson  Germany 
Regents 
Product Company Headquarters 
Dimethyl sulfoxide AppliChem Germany 
Isopropanol Walter CMP Germany 
L-glutamine Pan-Biotech Germany 
Trypan blue (0.02 %) Sigma-Aldrich Germany 
 
 
2.2 Evaluation of the expression of IgG in colon cancer cells 
In order to evaluate the accumulation of tumor-derived IgG in colon cancer cells, 4.0 × 105 
HROC277, HROC285, HROC370, or HROC374 cells were transferred into a tube and 
centrifuged at 300× g for 8 minutes. Subsequently, the cells were fixed with 400μL 2% formafix 
(Grim MED. Logistik GmbH, Torgelow Germany code1117264) for 15 minutes and washed by 
400μL 1× PBS (Table 3). Then these cells were incubated with 400μL 1× buffer P (Table 3) for 
10 minutes and centrifuged at 300× g for 8 minutes, followed by incubated with 200μL 1× buffer 
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P, 5μL goat anti-human IgG-heavy and light chain antibody FITC conjugated (Bethyl 
Laboratories, Montgomery, USA, code A80-119F) and 4μL mouse anti-human CD19 PE-
conjugated (ImmunoTools, Friesoythe, Germany, code 21270194) for 30 minutes. The 
fluorescent intensity of cells was measured by a BD FACSCalibur (Becton Dickinson, New 
Jersey, USA) and the data were analyzed by the software, BD CellQuest™ Pro (Becton 
Dickinson). 
 
Table 3. Required components of phosphate buffer saline (10×) and buffer P (100×) 
 
phosphate buffer saline (10×) 
Component Company Branch establishment 
80g Sodium chloride Carl Roth GmbH Karlsruhe, Germany 
2g Potassium chloride MERCK Darmstadt, Germany 
18.05g Di-sodium hydrogen phospate dihydrate MERCK Darmstadt, Germany 
1L Aqua dest - - 
buffer P (100×) 
Component Company Branch establishment 
0.5mL FBS Pan-Biotech Aidenbach, Germany 
5mL 1% saponin Carl Roth GmbH Karlsruhe, Germany 
5mL 0.1M HEPES AppliChem Darmstadt, Germany 
39.5mL 1× PBS - - 
 
 
2.3 Evaluation of cell viability 
In order to evaluate if human normal IgG can regulate cell viability, 1.2×104 HROC18, HROC46, 
HROC50, HROC87, HROC131, HROC147, HROC277, HROC277Met2, HROC278, HROC285, 
HROC370, HROC374 cells per well were seeded in a 96 well plate. In addition, to investigate if 
the human normal IgG influences the cytotoxic effect of oxaliplatin, 1.2×104 HROC277, 
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HROC285, HROC370, and HROC374 cells per well were seeded in a 96 well microplate. After 
24 hours, these cells were treated by Sham, PRIVIGEN® IgG, oxaliplatin, or the combination 
therapy, PRIVIGEN® IgG plus oxaliplatin, with the indicated concentrations given at each figure. 
After 5 days, these cells were washed by PBS and then stained by 0.2% crystal violet solution 
(Table 4) for 10 minutes, and the images were obtained with the help of a Plate scanner 
(Immunospot DC Suite Cellular Technology Ltd., Bonn, Germany). Subsequently, they were 
washed by PBS and incubated with 1% sodium dodecyl sulfate (SDS, Thermo Fisher 
Scientific,Waltham, USA, code 15525017) for 10 minutes and the optical density was measured 
at 570nm with the help of a Tecan Infinite 200 Microplate Reader (Tecan, Männedorf, 
Switzerland) and I-control 1.9 (Tecan Austria GmbH, Grödig, Austria).  
 
Table 4. Required components of 0.2% crystal violet solution 
 
Component Company Branch establishment 
200mg Crystal violet AppliChem Darmstadt, Germany 
2mL Ethanol absolute Walter CMP Kiel, Germany 
100mL Aqua dest. - - 
 
 
2.4 Evaluation of cell death  
In order to evaluate cell death, 2.0 ×105 HROC277, HROC285, HROC370, and HROC374 cells 
per well were plated in a 6 well plate and grown for 24 hours. Subsequently, these cells were 
treated by Sham, 5mg/mL PRIVIGEN® IgG, 6.25µM oxliaplatin, and the combinational therapy, 
PRIVIGEN® IgG plus oxaliplatin. After 48 hours, the supernatant was transferred to a FACS-tube 
and the cells were washed by 200μL PBS. After transferring the PBS into the tube, the 
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HROC277, HROC285, HROC370, and HROC374 cells were trypsinized by 200µL 0.025% 
trypsin at 37 °C. After 5-10 minutes, the cells were transferred into the FACS-tube and 
centrifuged at 300× g for 8 minutes. Then, the cells were washed with 500μL 1× binding buffer 
(Table 5) and centrifuged again. Re-suspension of cells was done with 70μL binding buffer, and 
staining with 5μL Annexin V-FITC (ImmunoTools, code 31490013) for 15 minutes at room 
temperature in the dark. Counter-staining of cells was done with 50µL propidium iodide (PI, 
PanReac AppliChem, Darmstadt, Germany, code A2261) and measuring intensity of Annexin V-
FITC at an excitation and emission wavelength of 488nm and 519nm, respectively, with the help 
of the BD FACSCalibur (Becton Dickinson). The intensity of PI was measured at an excitation 
and emission wavelength of 488nm/615nm, respectively. The percentage of dead cells, 100% × 
(Annexin V+ PI- + Annexin V+PI+ + Annexin V-PI+) cells/total cells, was determined with the 
help of the BD FACSCalibur and BD CellQuest™ Pro. In order to evaluate if oxaliplatin-induced 
cell death was dependent on the activity of ERK, 2.0 ×105 HROC277 and HROC285 cells were 
seeded in a 6 well plate. After 24 hours, these cells were treated by 50µM PD98059 (Cell 
Signaling, Massachusetts, USA, code 9900) or 10µM U0126 (Cell Signaling, code 9903S) for 1 
hour. Subsequently, these cells were washed by PBS and treated by 6.25µM oxaliplatin for 48 
hours, and the percentages of dead cells were determined as above-mentioned. 
 
Table 5. Required components of binding buffer (10×) 
 
Component Company Branch establishment 
0.1M HEPES AppliChem Darmstadt, Germany 
1.4M Sodium chloride Carl Roth GmbH Karlsruhe, Germany 




2.5 Evaluation of cell cycle 
In order to evaluate if IgG regulates cell cycle, 1.0×105 HROC18, HROC46, HROC50 or 
HROC87, HROC131, HROC147, HROC277, HROC277Met2, HROC278, HROC285, 
HROC370, HROC374 cells per well were seeded in a 24 well plate and grown for 24 hours. 
These cells were treated by Sham or 5mg/mL IgG for 48 hours. Similar to the process of 
measuring cell death, the supernatant and cells were transferred to a FACS-tube and were 
centrifuged. Subsequently, these cells were resuspended in 2mL 70% ethanol for 12 hours, and 
washed by 500µL 1× PBS twice. Then these cells were incubated by 400µL 0.1 % Tween 20 and 
5µL 1mg/mL RNase (Sigma-Aldrich, St. Louis, Missouri, USA, code 10109134001) at room 
temperature. The nuclei were stained by 50μL 0.1mg/ml PI and the intensity of PI was measured 
at an excitation and emission wavelength of 488nm/615nm with the help of the BD FACSCalibur 
and the data were analyzed by ModFit LT v3.3 (Becton Dickinson). 
 
2.6 Quantitative real-time PCR 
5.0 × 105 HROC285 cells per well grown in a 6 well plate for 24 hours were treated by Sham, 5 
mg/mL PRIVIGEN® IgG, 6.25µM oxaliplatin, and PRIVIGEN® IgG plus oxaliplatin for 1 hour 
and 24 hours. Subsequently, these cells were trypsinized and washed by 1× PBS. The isolation of 
RNA was performed following the manufacturer instructions of Universal RNA Purification Kit 
(EURx, Gdansk, Polska, code E3598). In short, cell pellets were re-suspended by 400μL buffer 
RL and 4μL β-mercaptoethanol (Carl Roth, Karlsruhe, Germany, code 4227.1), and were 
centrifuged for 3 minutes. Subsequently, the cell lysates were transferred into a fresh tube and 
mixed with 350μL 70% ethanol and were centrifuged for 3 minutes. Then the cell lysates were 
washed by 400μL Wash-RB1 buffer, 50μL DNR1, 1U DNase I buffer (Roche, Mannheim, 
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Germany, code 03539121103), 400μL Wash-RB1 buffer, and 40μL RNase free water (Carl Roth, 
code 154012146) as indicated in Fig. 4. The quality and quantity of RNA were evaluated by 
NanoDrop 1000 (Thermo Fisher Scientific, Waltham, USA) and RNAs were stored at -80 °C. 
 
Fig. 4. The process of RNA isolation. The isolation of RNA was performed by the manufacturer instructions of 
Universal RNA Purification Kit. The cell pellets were thoroughly mixed with 400μL buffer RL with 4μL β-
mercaptoethanol and centrifuged. The overlay was carefully transferred to the homogenizing column and 
centrifuged. The flow was added with 350μL 70% ethanol and mixed thoroughly by pipetting. Then transferred to 
RNA binding centrifugation columns and centrifuged. The flow was discarded and the column was returned to the 
collecting vessel then 400μL Wash-DN1 buffer was added before centrifugation. The flow was discarded and the 
column was returned to the collecting vessel. The column was incubated with 50μL buffer DNR1+1U DNase I for 
10min then filled with 400μL buffer Wash-RB1 and centrifuged. Two more wash steps were carried out with 650μL 
Wash-RBW buffer and 350μL Wash-RBW buffer. The column was placed on a new collecting vessel and 40μL 
RNase free water were added to the middle of the column membrane and centrifuged. The column was discarded. 




In order to synthesize complementary DNA (cDNA), 1µg RNA was diluted by RNase free water, 
as indicated in Table 6, and incubated with primers at 70 °C for 10 min with the help of a 
Thermal Cycler (Bio-Rad Laboratories, Munich, Germany). The master mix for one reaction was 
prepared as following: 4μL 5× RT buffer complete (Bioron, Ludwigshafen, Germany code: 
105100), 1μL 10 mM dNTP Mix (Bioron, code: U1511) and 1µL Reverase™ transcriptase 
(Bioron, code 105100). The synthesis reaction of cDNA was performed in the presence of 14µL 
diluted RNA and 6µL master mix at 45 °C for 120 minutes and 70 °C for 10 minutes. Finally, the 
cDNA was diluted by adding 60μL of RNase free water.  
 
Table 6. Dilution of RNA 
 
Component Volume (µL) 
mRNA (1µg) X 
Oligo(dT)15 Primer and random primer (Metabion, Planegg, Germany) 1.0 
RNase free water 14-X-1 
Total volume 14 
 
 
In order to perform PCR, the master mix (Table 7) plus 2µL cDNA or 2µL nuclease free water 
(negative control) was transferred into a 96 hard shall PCR-plate. Subsequently, the PCR reaction 
was run with the help of Bio-Rad Real-Time PCR System with the following conditions: 95 °C 
and 10 minutes for hold stage; 95 °C for 15 seconds and60°C for 30 seconds, 40 cycles for the 
PCR stage. Relative quantification analysis was performed by the comparative ΔCT method 
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(ΔΔCT Method) with following formulas: (1) ΔCT = CT target gene - CT ß-actin; (2) ΔΔCT = ΔCT 
treatment - ΔCT control; (3) Target gene expression of treated cells = 2 (-ΔΔCT) [72]. 
 
Table 7. Master mix for quantitative real-time PCR 
 
Component Volume (µL) 
SibirRoxHot MasterMix (Bioron, Ludwigshafen, Germany) 6,25 
Forward primer (10 pmol/µL, Metabion, Planegg, Germany) 0.625 
Reverse primer (10 pmol/µL, Metabion, Planegg, Germany) 0.625 
Nuclease free water (EUR x, Gdansk, Poland) 3 
Total volume 10.5 
 
 
2.7 Western blot 
In order to evaluate the accumulation of ERCC1 and the activity of ERK and p38, 5.0 × 105 
HROC285 or HROC277 cells were seeded in a 6 well plate. After 24 hours, these cells were 
treated by Sham, 5 mg/ml PRIVIGEN® IgG, 6.25µM oxaliplatin, or the combination therapy, 
PRIVIGEN® IgG plus oxaliplatin. After 24 hours or 48 hours, the HROC285 and HROC277 cells 
were lysed by 150µL lysis buffer. Western blots were performed as previously described [73]. 
The cell lysates were separated on 12% SDS polyacrylamid gels and the proteins were transferred 
to polyvinyldifluoride membranes (Immobilon-P; Millipore, Eschborn, Germany). In addition, 
2.5% (wt/vol.) BSA was used to block the membranes and they were incubated overnight at 4°C 
with following primary antibodies: mouse anti-ERCC1 (Santa Cruz Biotechnology, Texas, USA, 
code sc-17809, dilution: 100×), mouse anti-ERK (R&D Systems, Wiesbaden, Germany, code 
MAB15761, dilution: 500×), rabbit anti-phospho-ERK (p-ERK, R&D Systems, code MAB1018, 
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dilution: 1,000×), rabbit anti-p38 MAPK  (Cell Signaling, code 9212, dilution: 1,000×), rabbit 
anti-phospho-p38 MAPK (p-p38, Cell Signaling, code 9211, dilution: 1,000×), followed by the 
secondary antibodies: peroxidase-linked anti-rabbit-antibody (Cell Signaling, code 7074, 
dilution: 5,000-10,000×) or a peroxidase-linked anti-mouse antibody (Sigma-Aldrich, code 
A9044, dilution: 20,000-60,000×). In order to evaluate the accumulation of β-actin, all 
membranes were stripped and blocked by 2.5% (wt/vol.) BSA, followed by the incubation with 
mouse anti-β-actin antibody (Sigma-Aldrich, code A5441, dilution 1: 20,000×). Subsequently, the 
membranes were incubated by peroxidase-linked anti-mouse antibody (Sigma-Aldrich, code 
A9044, dilution 1: 60,000×). The accumulation of proteins was visualized by luminol-enhanced 
chemiluminescence (ECL plus; GE Healthcare, Munich, Germany) and was digitalized with 
Chemi-Doc XRS System (Bio-Rad). 
 
2.8 Evaluation of anti-cancerous effect of IgG and oxaliplatin in vivo 
The in vivo experiments were performed in accordance with the European Directive 
(2010/63/EU), and this procedure was approved by the local animal care committee (Landesamt 
für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern, permit 
number: LALLF M-V/TSD/7221.3-1-005/17). NOD.Cg-Prkdcscid II2rgtm1WjI/SzJ mice were bred 
in a local animal facility (Rostock University Medical Center, Rostock, Germany) and kept on 
water and standard laboratory chow ad libitum. The 6-8-week-old mice were anesthetized by 
intraperitoneal injection of narcotics (xylazine/ketamine 90/60mg/kg body weight) and the eyes 
were protected by eye ointment. After absent of kicking response, a RFID transponder was 
injected into the nuchal fold of mice and the body temperature of mice was kept at 38°C by a 
heating plate. Subsequently, a 0.5cm incision was performed on the right flank side of the mice 
22 
 
and a 3 × 3 × 3mm piece of tumor tissue was implanted. The incision was closed by two surgical 
knots and was sterilized by povidone-iodine solution. Subsequently, the mice recovered in a fresh 
cage and were warmed by an infrared lamp. In order to protect the mice from potential bacterial 
contaminations, antibiotic water was supplied to these mice for 6 weeks.  
After two weeks, the mice were started to be surveilled twice a week, and the diameter of tumors 
was determined, as indicated in Fig. 5, with the help of a caliper square. The volume of the tumor 
was calculated by the following formula: π/6 × [(large diameter + small diameter)/2]3 and the 
volume change were calculated by using the volume of tumor on day 0 (Fig. 5) as a reference for 
the respective cohort. When the tumor grew to 33.3-50.6mm3, the mice were injected with 0.9% 
Nacl (Sham), PRIVIGEN® IgG (sc), oxaliplatin (ip), or the combination therapy, PRIVIGEN® 
IgG plus oxaliplatin, as indicated in Fig. 5. Mice were euthanized when the tumor reached 
1,426mm3 or when they lost 20 % of the body weight. The tumor was cut into two pieces, one 
piece was preserved in 4% formafix and the other piece was sap-frozen and cryo-conserved. 
 
2.9 Data presentation and statistical analysis 
Data were presented as mean ± standard deviation (SD) or box plot. The distribution of data was 
evaluated by Shapiro-Wilk normality test, and the variance was determined by Levene median 
equal variance test. In order to determine the significance of differences, the data, which are 
normal distributed and equal in variance, were evaluated by two-way repeated measures analysis 
of variance with Holm-Sidak’s post hoc test. Otherwise, the data were analyzed by Mann-
Whitney U test and followed by the Bonferroni correction [74]. In addition, the inhibitory 
concentration (IC50) of oxaliplatin was determined by GraphPad Prism 8 (GraphPad Software, 
San Diego, California, USA) and the correlation between cancer cell-derived IgG and IC50 was 
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determined by Pearson’s correlation coefficient. All statistics were performed by Sigmaplot 12.0 




Fig. 5. Scheme of in vivo experiment. The treatments were started when the tumor grew to 33.3-50.6mm3. The 
distinct mouse cohorts were either Sham treated with 0.9% Nacl (ip) for 8 times in 4 weeks, with oxaliplatin 
(3.5mg/kg, ip) for 6 times in 4 weeks, with IgG (200mg/kg, sc) for 8 times in 4 weeks or the combinational therapy, 
IgG plus oxaliplatin. The mice were followed up for 4 weeks.   
OXA+IgG 
200 mg/kg IgG 
3.5 mg/kg OXA + 
 
3.5mg/kg OXA 














3.1       Clinical and pathological characteristics of patients 
In order to evaluate whether or not PRIVIGEN® IgG application benefits colon cancer patients, 
low-passage individual cell lines from 11 colon cancer patients were used in this study, and all 
these patients underwent surgery in our clinic. The mean age of these patients was 66.00 years ± 
14.04 years. Tumors were observed in cecum, ascending, descending, and sigmoid colon, and 
were all diagnosed as adenocarcinoma. In addition, the tumors of HROC18 and HROC370 were 
classified as UICC stage I; tumors of HROC50 and HROC87 were classified as UICC stage II; 
tumors of HROC131 and HROC374 were classified as UICC stage III; tumors of HROC46, 
HROC147, HROC277, HROC 278, HROC285 were classified as UICC stage IV.   
 
3.2       PRIVIGEN® IgG does not significantly influent cell viability 
In order to evaluate if PRIVIGEN® IgG has an effect on the viability of colon cancer cells, 
HROC18, HROC46, HROC50, HROC87, HROC131, HROC147, HROC277, HROC278, 
HROC285, HROC370, HROC374 cells were cultured in nutrition-rich (10% FBS) or starved (0% 
FBS) conditions (Fig. 6) and treated by Sham, 0.10mg/mL, 1mg/mL, and 10mg/mL PRIVIGEN® 
IgG for 5 days. This study proved that PRIVIGEN® IgG does not significantly (all P > 0.05) 





Fig. 6. PRIVIGEN® IgG fails to have a significant influence on the viability of colon cancers. The HROC18 
(A), HROC46 (B), HROC50 (C), HROC87 (D), HROC131 (E), HROC147 (F), HROC277 (G), HROC277Met2 (H), 
HROC278 (I) HROC285 (J), HROC370 (K), HROC374 (L) cells were cultured in medium with different 
concentrations of FBS and treated by Sham, 0.10mg/mL; 1mg/mL, and 10mg/mL IgG for 5 days.  PRIVIGEN® IgG 
did not significantly regulate the viability of these cells. n=5 for A and F; n=7 for B, G, H, I; n=6 for C, E, K, L; n=4 
for D; n=8 for J.   
26 
 
3.3       PRIVIGEN® IgG does not significantly regulate the cell cycles 
In order to evaluate if IgG regulates the cell cycle, HROC18, HROC46, HROC50, HROC87, 
HROC131, HROC147, HROC277, HROC277Met2, HROC278, HROC285, HROC370, 
HROC374 were cultured in 5% FBS medium and treated with 5mg/mL IgG for 2 days. IgG did 
not significantly (all P > 0.05) regulate the G0/G1, G2/M and S phases, when compared to Sham-
treated cells (Fig. 7). 
 
Fig. 7. PRIVIGEN® IgG fails to regulate the cell cycle. The HROC18 (A), HROC46 (B), HROC50 (C), HROC87 
(D), HROC131 (E), HROC147 (F), HROC277 (G), HROC277Met2 (H), HROC278 (I) HROC285 (J), HROC370 
(K), HROC374 (L ) cells were cultured in 5% FBS medium and treated with 5mg/mL IgG for 2 days. n=2 for A and 




3.4       PRIVIGEN® IgG cannot significantly regulate the anti-viability effect of 5-FU and  
irinotecan but significantly inhibits the anti-viability effect of oxaliplatin in vitro 
In order to evaluate if IgG can influence the anti-cancerous effect of 5-FU or irinotecan, four cell 
lines, HROC277, HROC285, HROC370, and HROC374 cells were treated with Sham, 
PRIVIGEN® IgG, 5-FU, irinotecan, or the combinational therapies, IgG in combination with 5-
FU or IgG in combination with irinotecan. The results demonstrated that 5-FU and irinotecan 
significantly (P < 0.001) inhibited the viability of HROC277 (Fig. 8), HROC285 (Fig. 9), 
HROC370 (Fig. 10), and HROC374 cells (Fig. 11), when compared with Sham-treated cells. 
However, 1.25mg/mL, 2.5mg/mL, and 5mg/mL IgG failed to significantly (P > 0.05) regulate the 
cell viability. In addition, IgG did not have significant (P > 0.05) influence on the anti-cancerous 
effect of 5-FU and irinotecan in HROC277 (Fig. 8), HROC285 (Fig. 9), HROC370 (Fig. 10), and 
HROC374 cells (Fig. 11). 
In order to evaluate if IgG regulates the cytotoxcity of oxaliplatin, HROC277 (Fig. 12), 
HROC285 (Fig. 12), HROC370 (Fig. 13), and HROC374 (Fig. 13), were treated with 
PRIVIGEN® IgG and oxaliplatin. The results proved that 2.50µM and 6.25µM oxaliplatin 
significantly (P < 0.001) inhibited HROC277 cell viability, when compared to Sham-treated 
cells; however, 1.25mg/mL, 2.5mg/mL, and 5mg/mL IgG failed to significantly (P > 0.05) 
regulate the viability of HROC277 cells (Fig. 12). Interestingly, 2.5mg/mL, and 5mg/mL IgG 
significantly (P < 0.001) inhibited the anti-viability effect of oxaliplatin in HROC277 cells (Fig. 
12). Very similar results were obtained with HROC285 (Fig. 12), HROC370 (Fig. 13), and 
HROC374 (Fig. 13) cells when they were treated with oxaliplatin and PRIVIGEN® IgG. This 




Fig. 8 PRIVIGEN® IgG does not significantly influence the anti-cancerous effects of 5-FU and irinotecan (IRI) 
in HROC277 cells. HROC277 cells were treated with Sham (A), PRIVIGEN® IgG (A), 10.76µM 5-FU (B), 
53.80µM 5-FU (C), 7.54µM IRI (D), 37.70µM IRI (E), or the combinational therapy for 5 days. 5-FU and IRI 
significantly inhibited cell viability, when compared to Sham-treated cells; however, PRIVIGEN® IgG did not have 




Fig. 9 PRIVIGEN® IgG does not have significant influence on the anti-cancerous effects of 5-FU and 
irinotecan (IRI) in HROC285 cells. HROC285 cells were treated with Sham (A), PRIVIGEN® IgG (A), 10.76µM 
5-FU (B), 53.80µM 5-FU (C), 7.54µM IRI (D), 37.70µM IRI (E), or the combinational therapy for 5 days. 5-FU and 
IRI significantly inhibited cell viability, when compared to Sham-treated cells; however, PRIVIGEN® IgG did not 




Fig. 10 PRIVIGEN® IgG does not have significant influence on the anti-cancerous effects of 5-FU and 
irinotecan (IRI) in HROC370 cells. HROC370 cells were treated with Sham (A), PRIVIGEN® IgG (A), 10.76µM 
5-FU (B), 53.80µM 5-FU (C), 7.54µM IRI (D), 37.70µM IRI (E), or the combinational therapy for 5 days. 5-FU and 
IRI significantly inhibited cell viability, when compared to Sham-treated cells; however, PRIVIGEN® IgG did not 




Fig. 11 PRIVIGEN® IgG does not have significant influence on the anti-cancerous effects of 5-FU and 
irinotecan (IRI) in HROC374 cells. HROC374 cells were treated with Sham (A), PRIVIGEN® IgG (A), 10.76µM 
5-FU (B), 53.80µM 5-FU (C), 7.54µM IRI (D), 37.70µM IRI (E), or the combinational therapy for 5 days. 5-FU and 
IRI significantly inhibited cell viability, when compared to Sham-treated cells; however, PRIVIGEN® IgG did not 




Fig. 12 PRIVIGEN® IgG impairs the cell-toxic effects of oxaliplatin (OXA) in HROC277 and HROC285. 
HROC277 (A-C) and HROC285 (D-F) cells were treated with Sham, PRIVIGEN® IgG, 2.50µM OXA (B and E), 
6.25µM OXA (C and F), or the combinational therapy for 5 days. OXA significantly inhibited cell viability, when 
compared to Sham-treated cells. Interestingly, PRIVIGEN® IgG significantly impaired the toxic effects of OXA.  




Fig. 13 PRIVIGEN® IgG impairs the cell-toxic effects of oxaliplatin (OXA) in HROC370 and HROC374. 
HROC370 (A-C) and HROC374 (D-F) cells were treated with Sham, PRIVIGEN® IgG, 2.50µM OXA (B and E), 
6.25µM OXA (C and F), or the combinational therapy for 5 days. OXA significantly inhibited cell viability, when 
compared to Sham-treated cells. Interestingly, PRIVIGEN® IgG significantly impaired the toxic effects of OXA. n=7 
for B and C; n=8 for E and F. 
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3.5        PRIVIGEN® IgG significantly reduces the oxaliplatin-induced cell death in vitro 
To evaluate how PRIVIGEN® IgG regulates cell death, HROC277 (Fig. 14A), HROC285 (Fig. 
14B), HROC370 (Fig. 15A), and HROC374 (Fig. 15B) cells were treated with 5mg/mL IgG and 
6.25µM oxaliplatin. The results proved that oxaliplatin significantly (P=0.002) increased the 
percentage of dead cells, when compared to Sham-treated cells in HROC277. In addition, the 
combinational therapy, IgG in combination with oxaliplatin, significantly (P=0.002) reduced the 
percentage of cell death, when compared to oxaliplatin-treated cells. Very similar results were 
obtained with HROC285 (Fig. 14B), HROC370 (Fig. 15A), and HROC374 (Fig. 15B) cells when 
they were treated with oxaliplatin and PRIVIGEN® IgG. This suggests that PRIVIGEN® IgG 
significantly impaired the oxaliplatin-induced cell death and led to oxaliplatin resistance.  
 
Fig. 14. PRIVIGEN® IgG decreases oxaliplatin-induced cell death in HROC277 and HROC285. HROC277 and 
HROC285 cells were incubated with Sham, 6.25µM oxaliplatin (OXA), 5mg/mL PRIVIGEN® IgG, or OXA in 
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combination with IgG for 48 hours. 6.25µM OXA significantly induced cell death, when compared to Sham-treated 
cells. In addition, IgG significantly inibited OXA cytotoxcity, when compared to OXA-treated cells. n=6 for A and B. 
 
 
Fig. 15. PRIVIGEN® IgG decreases oxaliplatin-induced cell death in HROC370 and HROC374. HROC370 and 
HROC374 cells were incubated with Sham, 6.25µM oxaliplatin (OXA), 5mg/mL PRIVIGEN® IgG, or OXA in 
combination with IgG for 48 hours. 6.25µM OXA significantly induced cell death, when compared to Sham-treated 
cells. In the combinational therapy, OXA-triggered cell death significant decreased. n=6 for A; n=11 for B. 
 
3.6 Tumor cell-derived IgG is positively correlated with intrinsic resistance to oxaliplatin 
Subsequently, the study investigated if colon cancer cells express IgG and if this intrinsic IgG 
leads to oxaliplatin resistance. The study demonstrated that all four low passage colon cancer cell 
lines, HROC277, HROC285, HROC370 and HROC374 generated IgG. Interestingly, the 
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percentage of tumor cell-derived IgG-expressing cells in  HROC277 or in HROC285 cells was 
significantly higher than that in HROC370 and HROC374 cells (Fig. 16). 
 
Fig. 16. The expression of tumor cell-derived IgG in colon cancer cells. The percentage of IgG+CD19- in 
HROC277 and in HROC285 cells was significantly higher than that in HROC370 and HROC374 cells. n=6. 
 
Next, we determined the IC50 of oxaliplatin for these HROC cell lines. After treating cells with 
1µM oxaliplatin for 5 days, compared to Sham treatment, only 38.51% of HROC277 cells and 
33.94% of HROC 285 cells were killed by 1µM oxaliplatin; however, 1µM oxaliplatin killed 
64.44% of HROC370 and 63.00% of HROC374 cells (Table 8).   
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                   Table 8. Inhibition of cell viability (Compared to Sham-treated cells) 
 
OXA (µM) HROC277 HROC285 HROC370 HROC374 
0.00  0.00% 0.00% 0.00% 0.00% 
1.00  38.51% 33.94% 64.44% 63.00% 
2.50 50.68% 58.37% 68.89% 76.56% 
6.25 62.16% 84.16% 74.22% 80.22% 
15.63 76.35% 83.26% 79.11% 80.95% 
 
Subsequently, the IC50 values for oxaliplatin of HROC277, HROC285, HROC370, and 
HROC374 cells were caculated (Fig. 17). The IC50 value of HROC285 cells (1.79/1.55-2.11) was 
nearly 4.6-fold higher than that of HROC370 cells (0.35/0.23-0.41, Fig. 17) or of HROC374 cells 
(0.34/0.18-0.41, Fig. 17). The increase was more than 6-fold, when comparing HROC277 cells 
(2.40/2.17-2.76) to HROC370 (0.35/0.23-0.41) or HROC374 cells (0.34/0.18-0.41). This 
suggests that HROC277 and HROC285 cells are intrinsically resistant to oxaliplatin; at least in 
direct comparison to HROC370 or HROC374 cells. In addition, we evaluated if the level of 
tumor cell-derived IgG is correlated with the IC50 of oxaliplatin. The Pearson’s correlation 
coefficient suggests that there is a strong positive correlation between the level of intrinsic IgG 
and oxaliplatin resistance (Pearson’s correlation coefficient = 0.769; P < 0.001; Fig. 17).               
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Fig. 17. Tumor cell-derived IgG is positively correlated with intrinsic resistance to oxaliplatin. The IC50 value 
for oxaliplatin (A) in HROC277 (red box or dots) and HROC285 cells (blue box or dots) is significantly higher than 
that of HROC370 cells (pink box or dots) or of HROC374 cells (green box or dots). The Pearson’s correlation 
coefficient (B) demonstrated a strong positive correlation between the level of intrinsic IgG and oxaliplatin resistance 
(Pearson’s correlation coefficient = 0.769; P < 0.001). n=6 for A and B. 
 
3.7 PRIVIGEN® IgG fails to significantly impair the anti-cancerous effect of oxaliplatin 
in vivo 
In order to verify the in vitro results, tumor tissues of patient HROC285 were implanted into the 
right flank of immunodeficient mice and were treated with Sham, PRIVIGEN® IgG, oxaliplatin, 
or IgG in combination with oxaliplatin as indicated in Fig. 5. The results proved that oxaliplatin 
inhibited the tumor growth, when it was compared to Sham-treated mice (P = 0.032, Fig. 18). 
However, IgG (P = 0.841) cannot significantly inhibit the tumor growth, when the increased 
tumor volume was compared to Sham-treated mice. IgG failed to significantly (P = 0.429) impair 
the anti-cancerous effect of oxaliplatin, when the increased tumor volume in combinational 




Fig. 18. PRIVIGEN® IgG fails to significantly impair the anti-cancerous effect of oxaliplatin in vivo. OXA 
inhibited tumor growth, when compared to Sham-treated mice (P = 0.032); IgG failed to significantly (P = 0.429) 
impair the anti-cancerous effect of oxaliplatin. n=5 for Sham; n=6 for IgG and OXA; n=7 for IgG+OXA. 
 
3.8 PRIVIGEN® IgG fails to influence the accumulation of ERCC1 and p38 activity but 
inhibits the oxaliplatin-induced ERK activity 
In order to evaluate if ERCC1 is involved in the IgG mediated resistance to oxaliplatin, 
HROC285 cells were treated by Sham, oxaliplatin, PRIVIGEN® IgG, and oxaliplatin in 
combination with IgG for 1 hour (Fig. 19A) or 24 hours (Fig. 19B) and the expression of ERCC1 
mRNA was measured. Oxaliplatin and IgG failed to significantly influence the accumulation of 
ERCC1 mRNA. To investigate if IgG regulates the accumulation of ERCC1, the HROC285 cells 
were treated by Sham, oxaliplatin, PRIVIGEN® IgG, and oxaliplatin in combination with IgG for 
Days 























24 hours (Fig. 19C) and 48 hours (Fig. 19D). Neither oxaliplatin nor IgG did have influence on 




Fig. 19. Expression of ERCC1. HROC285 cells were treated with Sham, 5mg/ml IgG, 6.25µM oxaliplatin (OXA) 
and combinational therapy (IgG plus OXA). OXA and IgG failed to influence the accumulation of ERCC1 on both, 
RNA and protein levels. n=3 for A, B, C, and D. 
 
In order to investigate if the MAPKs signaling pathway is involved in the IgG mediated 
resistance to oxaliplatin, we applied PRIVIGEN® IgG and oxaliplatin to HROC285 cells and 
measured the activity of p38 and p-ERK, two master proteins of the MAPK pathway. Both IgG 
and oxaliplatin failed to activate p38 in HROC285 cells (Fig. 20A and B), while oxaliplatin 
markedly induced ERK activity and IgG inhibited the activity of ERK, when compared to Sham-
treated cells (Fig. 20A and B). In addition, IgG inhibited the oxaliplatin-induced ERK activity in 
HROC285 cells (Fig. 20A and B). To verify these findings, we applied IgG and oxaliplatin to 
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another colon cancer cell line, HROC277. Again, oxaliplatin induced the activity of ERK in 
HROC277 cells; however, IgG reduced the oxaliplatin-induced ERK (Fig. 20C and D).  
 
Fig. 20. IgG reduces the oxaliplatin-induced ERK activity. HROC285 (A and B) and HROC 277 (C and D) cells 
were treated with Sham, 5mg/ml IgG, 6.25µM oxaliplatin (OXA) and combination therapy (IgG plus OXA) for 24h 
and 48h. OXA activated ERK in HROC285 cells and HROC277 cells; however, IgG inhibited the oxliplatin-induced 
ERK activity. n=2 for A and B; n=3 for C and D. 
 
3.9 Inhibition of ERK activity reduces oxaliplatin-induced cell death 
In order to evaluate whether or not oxaliplatin cytotoxicity is dependent on ERK activity, a 
traditional inhibitor of ERK signaling, PD98059 was applied. PD98059 had no significant 
influence on the percentage of dead cells; however, oxaliplatin significantly induced cell death, 
when compared to Sham-treated cells in HROC285 (Fig. 21A) and HROC 277 (Fig. 21B). 
42 
 
Notably, PD98059 reduced the oxaliplatin-induced cell death in both cell lines (Fig. 21A and B). 
To verify these findings, HROC285 and HROC277 cells were treated with another inhibitor, 
U0126, of the ERK pathway and similar results were obtained (Fig. 21C and D). This suggests 
that the MAPKs signaling pathway is involved in the cytotoxicity effect of oxaliplatin. 
 
Fig. 21. Inhibition of ERK activity leads to oxaliplatin resistance. HROC285 and HROC277 cells were pretreated 
with 50µM PD98059 (PD) and 10µM U0126. Subsequently, these cells were treated by oxaliplatin (OXA) for 48 
hours. OXA significantly increased the percentage of cell death, when compared to Sham-treated cells (A-D). 
However, PD98059 (PD) (A and B) and U0126 (C and D) significantly decreased the OXA-induced cell death. n=5 







4.1 Patient derived xenograft model is a valuable platform for translational cancer 
research 
For drug development, evaluating efficacy and toxicity of new compounds in preclinical is 
essential. Thus, development of an animal model, which appropriately mimics human tumor 
biology, is a core necessity in successful future drug development.  
The traditional tumor model is to develop a cell line and to inject the cells into mice. A limitation 
of this strategy is that such models cannot sufficiently mimic the tumor biology of humans. For 
example, some factors of the tumor microenvironment, such as cancer associated fibroblasts and 
extracellular matrix are missing in such models. Thus, numerous chemical compounds have 
shown promising anti-cancerous activity using this strategy; but most of them failed to inhibit 
tumor growth and development of metastases in humans [75].  
In recent years, PDX have become a preferred preclinical tool for drug development [76]. In 
order to appropriately mimic human tumor biology, the human tumor tissues are directly 
transplantation into immunodeficient mice. This preserves the genetic, histological and 
phenotypic characteristics of the tumor. In addition, this model also preserves the 
microenvironment of tumors. Thus, the PDX model is a valuable platform for translational cancer 
research, especially for drug development [75]. 
However, there are still some limitations of this model. Firstly, the PDX model needs to use 
immunodeficient mice for tumor engraftment and propagation. Thus, this model cannot be used 
to evaluate the anti-cancerous effect of novel immunotherapeutics like for example checkpoint 
inhibitors [75]. Secondly, some researchers recommend using individual PDX models to 
44 
 
determine the optimal chemotherapeutic strategies for a given cancer patient and some studies 
have proven that PDX are a promising tool for personalized medicine. However, it usually takes 
4-8 months to develop a PDX model for a preclinical study, and this time delay limits the 
applicability of PDX models [76]. 
 
4.2 Oxaliplatin-based chemotherapy regimens for colon cancer 
Consistent with previous studies, we also observed that oxaliplatin, 5-FU and irinotecan can 
significantly impair cell viability. Currently, there are 31 kinds of drugs which have been 
approved by the U.S. Food and Drug Administration for treating colon cancers [77] and the 
NCCN Clinical Practice Guideline recommends the following 5 combinational chemotherapy 
regimens for colon cancer: 5-FU plus leucovorin (5-FU/LV), CAPOX, FOLFOX, FOLFIRI, and 
FOLFOXIRI [78]. 
 
4.3 Tumor cell-derived IgG is positively correlated with oxaliplatin resistance  
Traditionally, B-lymphocytes are thought to be the only source of IgG. However, recent evidence 
proves that tumor cells can generate and secret IgG [45, 62, 79, 80]. For example, Kimoto has 
detected the constant region of heavy chains in human colon, esophagus and breast carcinoma 
[81]. Another study detected the light chain of IgG in colorectal and breast carcinoma [82, 83]. 
Interestingly, some studies proved that cancer-derived IgG decreases the programmed cell death 
and promotes tumor growth [84]. Additionally, Liao et al. reported that high expression of IgG in 
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epithelial stem cells might lead to tumor metastasis [85]. Of note, no study evaluated if IgG can 
regulate the antitumor effect of chemotherapy.  
Consistent with previous studies [62, 80], this study also proved that tumor cells could generate 
IgG. In addition, this study for the first time proved that the tumor cell-derived IgG is positively 
correlated with intrinsic resistance to oxaliplatin. However, the present study did not evaluate if 
stimulation or inhibition of the tumor cell-derived IgG can influence oxaliplatin resistance. In 
addition, this study only evaluated the accumulation of tumor cell-derived IgG in four human cell 
lines. Thus, further studies need to verify if tumor cell-derived IgG leads to intrinsic resistance to 
oxaliplatin. 
 
4.4 Human IgG fails to influence cell viability but significantly induced oxaliplatin 
resistance in vitro 
Contradictory to previous studies [67], the results of the present study suggest that application of 
human IgG to treat cancer patients might fail to benefit patients’ outcome. This hypothesis is 
supported by two observations of our study: First, IgG could not significantly inhibit cell 
viability. Second, simultaneously treating cells with IgG and oxaliplatin reduced the cytotoxic 
effect of oxaliplatin. However, previous studies suggested that treating cancer patients with 
intravenous IgG might benefit patients. For example, Merimsky et al. proved in a preclinical 
analysis that intravenous IgG induced a dose-dependent inhibition of cell proliferation in Nb2-
11C lymphoma cells, MCA-105 sarcoma cells and HCT-116 colon cancer cells [68]. 
Interestingly, the present study proved that PRIVIGEN® IgG significantly inhibited the cytotoxic 
effect of oxaliplatin in vitro; however, IgG failed to significantly impair the anti-cancerous effect 
of oxaliplatin in vivo (Fig. 18). This can be explained by a limitation of this study: I administrated 
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IgG subcutaneously; however, most animal studies on IgG injected via the tail veins [86]. The 
subcutaneous injection might result in weak IgG absorption by vascular endothelial cells, and 
therefore IgG failing to reach an effective concentration in the blood.  
 
4.5 The interaction of ERK activity and oxalipatin resistance  
ERK is an important member of the MAPKs signaling pathway, which regulates a wide range of 
cellular activities and physiological processes [87]. Traditionally, activation of ERK can induce 
cell proliferation and differentiation [87]. In addition, Xu et al. observed that the accumulation of 
phosphorylated ERK in oxaliplatin-sensitive cells is lower than that in cells resistant to 
oxaliplatin [88]. Depletion of oxaliplatin-induced ERK activity reduced oxaliplatin resistance 
[88]. These observations suggest that activation of ERK leads to oxaliplatin resistance. 
Surprisingly, the present study proved that IgG as well as PD98059 and U0126, two traditional 
and specific inhibitors of the ERK signaling pathway, impaired ERK signaling and that this 
triggered oxaliplatin resistance. Interestingly, although IgG, PD98059 and U0126 inhibited the 
ERK activity, all of them could not significantly regulate the cells’ viability and death. This 
suggests that the function of ERK is context-dependent and inhibition of ERK signal pathway 
cannot always benefit patients. Thus, even though a number of preclinical studies proved that 
inactivation of ERK is a promising treatment strategy in several cancers [87, 88] and with even a 
clinical trial ongoing (ClinicalTrials.gov Identifier: NCT02420795), the data of this study suggest 
that mode of action and potential benefits of ERK inhibitors should be fully investigated before 
clinical application in cancer patients’ treatment. 
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Interestingly, a recent study reported that the clinical sequences of cetuximab, an inhibitor of 
EGFR, and oxaliplatin administration could lead to different responses of colon cancer cells to 
oxaliplatin [89]. The authors observed that cetuximab inhibited the cytotoxic effect of oxaliplatin 
when administered before oxaliplatin; however, cetuximab provided additive effects when 
administered after oxaliplatin [89]. In addition, administration of cetuximab before oxaliplatin 
induced the phosphorylation of ERK when compared to the inverse treatment strategy with 
administration of cetuximab after oxaliplatin therapy [89]. However, the present study only 
evaluated the strategy of simultaneously treating colon cancer cells by IgG and oxaliplatin. If 
different sequences of IgG and oxaliplatin cause different responses of colon cancer cells to 
oxaliplatin, this needs to be evaluated in a future study 
 
4.6 The interaction of ERCC1 or p38 activity and oxalipatin resistance 
During DNA damage, cells can activate several DNA repair systems, such as the nucleotide 
excision repair pathway [90]. This pathway can eliminate the lesions of DNA by the activity of 
ERCC1, and enhance the re-synthesis and ligation of DNA (Fig. 22) [91]. A body of evidence 
demonstrates that ERCC1 is involved in the resistance to platinum compounds [91]. For example, 
Youn et al. proved that ERCC1 could protect embryonic fibroblasts and breast cancer cells from 
platinum-based anticancer drugs [92]. In addition, Olaussen et al. reported that cisplatin-based 
therapy improved survival only in patients with ERCC1 negative tumors [93]. However, in the 
present study, ERCC1 was not involved in IgG-mediated oxaliplatin resistance. This suggests that 





Fig. 22. ERCC1 impairs platinum-mediated DNA damage. ERCC1 can eliminate the platinum-DNA adducts and 
thus restore the DNA replication. 
 
P38 is another member of the MAPKs signaling pathway, and it is known as “stress-activated 
protein kinases”. Totally, there are four genes, MAPK14, MAPK11, MAPK12, MAPK13, 
encoding of p38α, p38β, p38γ, and p38δ, respectively [94]. Although p38α and p38β have the 
same function; p38β is highly rare in most cell types and its contribution to p38 MAPK signaling 
is not clear [94]. In addition, p38γ and p38δ are not involved in the signal transmission of the p38 
MAPK pathway [94].  
Similar to ERK, p38 MAPK is also involved in several cellular activities and physiological 
processes, such as inflammation, differentiation and cell death [95], and it is activated by MAPK 
kinase kinases (MAPKKKs/MAP3Ks)-MAPK kinases (MAPKKs/MAP2Ks) pathway. Two 
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MAP2Ks, MKK3 and MKK6 can directly activate p38 MAPK, and these MAP2Ks can be 
activated by MAP3K4 (also known as MEKK4) via targeting AVRB operation1 and 2 [96].  
A body of evidence demonstrates that p38 is a tumor suppressor, which inhibits the proliferation 
and induces cell death [97]. For example, Zuluaga et al. proved that p38 induces cardiomyocytes’ 
death by up-regulation of the pro-apoptotic proteins, such as Fas and Bax, and down-regulation 
of the activity of the ERK and Akt survival pathways [98]. Additionally, Maria et al. proved that 
α-cyano-4-hydroxycinnamate could active the p38 MAPKs pathway. Inhibition of the p38 
signaling pathway by PH-797804 impaired the α-cyano-4-hydroxycinnamate-induced apoptosis 
[99]. However, the present study proved that p38 was not involved in the oxaliplatin-mediated 
cell death. This suggests that the tumor suppressive activity of p38 MAPK may be context-
dependent. 
 
4.7 The potential mechanisms of IgG-mediated oxaliplatin resistance  
The present study demonstrated that IgG induces oxaliplatin resistance by inhibiting ERK 
activity. Notably, some other mechanisms may be also involved in the IgG-mediated oxaliplatin 
resistance. 
4.7.1 Nucleotide excision repair system 
Several pieces of evidence proved that the nucleotide excision repair system is a master regulator 
of  cell sensitivity to platinum-based drugs [100]. The nucleotide excision repair system can 
excise the platinum-DNA adducts and repair the damaged DNA. Indeed, both cisplatin- and 
oxaliplatin-mediated DNA damage can be repaired by the nucleotide excision repair system 
[101]. Interestingly, the present study proved that IgG caused colon cancer cells resistance to 
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oxaliplatin (Fig. 12 and 13), but not to 5-FU and irinotecan (Fig. 8-11). Thus, we assume that IgG 
causes oxaliplatin resistance by impairing oxaliplatin-DNA adducts. 
 
4.7.2 Drug accumulation and detoxification proteins  
It has been proven that the intracellular accumulation of drugs and the activity of detoxification 
proteins are also two mechanisms causing cell resistance to platinum derivatives [102]. For 
example, a previous study proved that the major copper influx transporter CTR1 is involved in 
the transport of oxaliplatin, and that decreasing the accumulation of CTR1 can trigger oxaliplatin 
resistance [103]. In addition, depletion of glutathione (GSH), an antioxidant protein, by β-
phenylethyl isothiocyanate could enhance the cytotoxic effects of oxaliplatin [104]. This suggests 
that GSH might also cause oxaliplatin resistance. However, other studies demonstrated that GSH 
was not correlated with oxaliplatin resistance [105, 106].  
 
4.7.3 Hippo pathway  
Recent evidence suggests that the Hippo pathway might be another mechnism of IgG-induced 
oxaliplatin resistance [107, 108]. In mammals, several proteins are involved in the Hippo 
signalling pathway [108], such as the mammalian sterile 20-like kinases (MST1 and MST2, 
MST1/2), the large tumor suppressor kinases (LATS1 and LATS2, LATS1/2), the yes-associated 
protein (YAP) and the TEA domain family (TEAD1-4) transcription factors (Fig. 23)[108].  
When the Hippo pathway is swithced “ON”, the mammalian sterile 20-like kinases (MST1 and 
MST2, MST1/2) and Salvador homolog 1 (SAV1) activate the large tumor suppressor kinases 
(LATS1 and LATS2, LATS1/2) and phosphorylate yes-associated protein1 (YAP1). This leads to 
cytoplasmic retention and degradation of YAP1. However, when the signaling pathway is 
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switched “OFF”, YAP translocates to the nucleus and binds to some transcription factors such as 
TEA domain (TEAD) family transcription factors. These complexes activate the transcription of 
various genes.  
Initially, the Hippo signal pathway has been reported to control organ size [108]. However, recent 
studies suggest that YAP1 is also involved in chemoresistance to cisplatin [109] and oxaliplatin 
[110]. Interestingly, other studies reported that YAP1 interacts with p73 and enhanced the p73-
dependent apoptosis in response to DNA damage [108, 111]. These conflicting functions suggest 
that YAP1-induced oxaliplatin resistance may be context-dependent. Thus, a further study is 
needed to evaluated if and how IgG regulates YAP1 activity, and if the interaction of IgG and 





Fig. 23.  Hippo signaling pathway. Several signals, such as G-protein-coupled receptor signaling, protein kinase A 
and cyclic adenosine monophosphate, can stimulate and switch “ON” the Hippo pathway and impair YAP1 nuclear 
localization [108].  
 
4.7.4 Autophay 
Autophagy is a natural process controlling the recycling of unnecessary or dysfunctional 
components in the cell (Fig. 24) [74]. The damaged cell orgenelles and proteins are enclosed by 
isolation membranes and form the so-called autophagosomes. Subsequently, lysosomes fuse with 
autophagosomes and form autolysosomes. This leads to the degradatiuon and recycling of 
dysfunctional components [74]. 
 
 
Fig. 24. The schema of autophagy.  The intracellular or extracellular stimulators, such as hypoxia, starvation and 
infection can induce the formation of isolation membranes. The isolation membranes engulf the damaged cell 
organelles and proteins and form the autophagosomes with the help of LC3II and p62. Subequently, the organelles 
and proteins are transported to lysosomes by the fusion of autophagosomes and lysosomes, and degraded in the 




Interestingly, multiple studies reported that, in cancer cells, autophagy not only recycles 
dysfunctional components, but also impairs the anticancerous effect of oxaliplatin [112-114]. For 
example, Xiong et al. proved that inhibition of autophagy by chloroquine (CQ), a traditional 
inhibitor of autophagy, could increase oxaliplatin-induced cell death [113]. In addtion, two 
clinical trials (ClinicalTrials.gov Identifier: NCT01006369 and NCT01206530), which evaluate 
the benefit of oxaliplatin-based chemotherapeutics in combination with CQ, have been completed 
and the results may be available later in 2019. However, Soyeon et al. proved that induction of 
autophagy increased the oxaliplatin-induced cell death [113]. This suggests that inhibition of 
autophagy might not always benefit patients receving oxaliplatin. Thus, a further study is 
recommended to evaluate if and how autophagy is involved in the IgG-mediated oxaliplatin-
resistance. 
 
5. Conclusions and outlook 
The present study demonstrated that supplementation of human IgG impairs the anti-viability 
effect of oxaliplatin and reduces the oxaliplatin-mediated cell death. Interestingly, tumor cells 
also can genereate IgG and this intrinsic IgG is positively correlated with oxaliplatin resistance. 
In addition, this study proved that oxaliplatin activates ERK signaling pathway and inhibition of 
ERK activity by IgG or PD98059 and U0126, two tranditional inhibitors of ERK significantly 
reduced the oxaliplatin-mediated cell death. This suggests that IgG leads to oxaliplatin resistance 
might by inhibiting the ERK signal pathway.  
I think it would be interesting for future research to investigate how downstream proteins of the 
ERK transduction pathway are involved in the interaction of IgG and oxaliplatin. In addition, the 
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oxaliplatin-based regimens, FOLFOX and FOLFOXIRI, are currently evaluated for treatment of 
other cancer types such as pancreatic, rectal and esophageal cancer (https://clinicaltrials.gov/). 
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7. Thesis statement
• Recent evidence proves that intravenous immunoglobulin G (IgG) can impair cancer
cells.
• Cancer cells can produce and secreat IgG, and that tumor cell-derived IgG promotes
tumor initiation
• No study evaluated whether or not IgG application benefits cancer patient who is
receiving chemotherapeutics.
• Human normal IgG (PRIVIGEN®) cannot significantly influence tumor cell viability and
cell cycle.
• Human normal IgG (PRIVIGEN®) significantly impairs the anti-cancerous effects of
oxaliplatin.
• Tumor cell-derived IgG were positively correlated with oxaliplatin resistance.
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